Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Osteal Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Osteal Therapeutics

Osteal Therapeutics

Series C

Joint Purification Systems, Inc.: Innovating in pharmaceuticals and medical devices for musculoskeletal care.

HQ
Dallas, TX, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Osteal Therapeutics, originally known as Joint Purification Systems, Inc., was founded with the mission to revolutionize the treatment of orthopedic infections. The company's vision is to preserve limbs and lives by providing innovative pharmaceutical and medical device solutions for musculoskeletal care. Osteal Therapeutics develops novel drug and device combination products aimed at enabling orthopedic surgeons to effectively and swiftly address infections, thereby improving patient outcomes.

Notable affiliated individuals and investors include experienced professionals in the pharmaceutical and medical device industries, although specific names are not publicly detailed. Key achievements for Osteal Therapeutics include the development of groundbreaking treatments that have significantly impacted the standard of care for orthopedic infections. The company's relentless innovation has positioned it as a leader in musculoskeletal therapeutics, making a profound difference in the lives of patients suffering from these challenging conditions.

Osteal Therapeutics - Quick Facts

When was Osteal Therapeutics founded?

Osteal Therapeutics was founded in 2014.

Where is Osteal Therapeutics' headquarters located?

Osteal Therapeutics' headquarters is located in Dallas, TX, US.

When was Osteal Therapeutics' last funding round?

Osteal Therapeutics' most recent funding round was for $23M (USD) in September 2023.

How much has Osteal Therapeutics raised to-date?

As of Sep 21, 2023, Osteal Therapeutics has raised a total of $62.8M (USD).

How many employees does Osteal Therapeutics have?

Osteal Therapeutics has 15 employees as of Feb 5, 2024.

Osteal Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medical Devices
  • Pharmaceuticals
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified